Control of metabolic predisposition to cardiovascular complications of chronic kidney disease by effervescent calcium magnesium citrate: a feasibility study

Henry Quiñones2 · Tamim Hamdi2 · Khashayar Sakhaee1,2,3 · Andreas Pasch4 · Orson W. Moe1,2,5 · Charles Y. C. Pak1

Received: 2 August 2018 / Accepted: 16 November 2018 / Published online: 21 November 2018 © The Author(s) 2018

Abstract

Aims Cardiovascular (CV) complications are common in chronic kidney disease (CKD). Numerous metabolic disturbances including hyperphosphatemia, high circulating calciprotein particles (CPP), hyperparathyroidism, metabolic acidosis, and magnesium deficiency are associated with, and likely pathogenic for CV complications in CKD. The goal of this feasibility study was to determine whether effervescent calcium magnesium citrate (EffCaMgCit) ameliorates the aforementioned pathogenic intermediates.

Methods Nine patients with Stage 3 and nine patients with Stage 5D CKD underwent a randomized crossover study, where they took EffCaMgCit three times daily for 7 days in one phase, and a conventional phosphorus binder calcium acetate (CaAc) three times daily for 7 days in the other phase. Two-hour postprandial blood samples were obtained on the day before and on the 7th day of treatment.

Results In Stage 5D CKD, EffCaMgCit significantly increased T50 (half time for conversion of primary to secondary CPP) from baseline by 63% ($P = 0.013$), coincident with statistically non-significant declines in serum phosphorus by 25% and in saturation of octacalcium phosphate by 35%; CaAc did not change T50. In Stage 3 CKD, neither EffCaMgCit nor CaAc altered T50. With EffCaMgCit, a significant increase in plasma citrate was accompanied by statistically non-significant increase in serum Mg and phosphate. CaAc was without effect in any of these parameters in Stage 3 CKD. In both Stages 3 and 5D, both drugs significantly reduced serum parathyroid hormone. Only EffCaMgCit significantly increased serum bicarbonate by 3 mM ($P = 0.015$) in Stage 5D.

Conclusions In Stage 5D, EffCaMgCit inhibited formation of CPP, suppressed PTH, and conferred magnesium and alkali loads. These effects were unique, since they were not observed with CaAc. In Stage 3 CKD, neither of the regimens have any effect. These metabolic changes suggest that EffCaMgCit might be useful in protecting against cardiovascular complications of CKD by ameliorating pathobiologic intermediates.

Keywords Calciprotein particles · Chronic kidney disease · Cardiovascular complications · Magnesium · Citrate

Introduction

CKD is widely prevalent globally [1]. The prevalence of CKD increases progressively with advancing age [2]. Nearly one million persons have end stage renal disease and are treated with hemodialysis (Stage 5D) in the United States [3]. Among patients with CKD, the leading cause of death is cardiovascular complications composed of cardiomyopathy and vascular calcification [4].

There is emerging evidence that cardiovascular complications are likely causally linked to mineral derangements in CKD [5–7]. One such pathophysiologic intermediate is the formation of CPP, which are aggregates of...
calcium phosphate nanoparticles organized with various proteins with the main component being fetuin, wherein insoluble calcium phosphate is “solubilized” by combining and becoming coated with fetuin [8]. High serum CPP has been reported in patients with CKD [9, 10] and CPP might initiate vascular calcification and cardiomyopathy [11] by induce various cellular responses, including production of reactive oxygen species, mitochondrial dysfunction, cell cycle arrest, and cell death [12]. Serum CPP correlates positively with coronary artery calcification score [9], worsening of kidney function [9], and with all-cause mortality among patients with CKD [13]. To tests CPP’s pathogenic role in cardiovascular complications of CKD, it is necessary devise a countermeasure that would inhibit CPP formation as well as overcome cardiovascular complications.

In addition to CPP formation, CKD-MBD has a wide spectrum of abnormalities that may represent pathophysiologic intermediates of CV disease including hyperphosphatemia [14–16], hyperparathyroidism [17], metabolic acidosis [18], and magnesium deficiency [19] based on epidemiologic association as well as experimental evidence. We hypothesized that EffCaMgCit might be a countermeasure to all the pathophysiologic parameters mentioned above (Table 1). Its provision of optimally soluble and bioavailable magnesium and citrate should deter CPP formation [10, 20], and its magnesium and alkali load should also be cardioprotective [21, 22]. The testing of this hypothesis required the demonstration of not only biochemical improvement but also beneficial effects on cardiovascular function and clinical outcome. Acknowledging that such a goal carries a large commitment of resources with uncertain outcome, we decided to first conduct a feasibility study.

We report here the results of feasibility study in 9 patients with CKD Stage 3, and 9 patients with CKD Stage 5D, who underwent a randomized crossover trial wherein each received EffCaMgCit or CaAcS for 7 days. The striking findings on serum propensity for CPP formation and other metabolic parameters prompted us to share this preliminary report.

### Materials and methods

#### Subjects

Patients were recruited from the nephrology clinic in University of Texas Southwestern Medical Center (UT Southwestern) and Joint Venture DaVita-UT Southwestern dialysis practices in Dallas. All protocols were approved by the Institutional Review Boards at UT Southwestern and DaVita and all patients gave informed consent in their chosen language. 9 patients with Stage 3 CKD and 9 patients with Stage 5D CKD on hemodialysis participated in the study. In Stage 3, 7 were men and 2 women, ranging in age from 50 to 80 years (mean 71). Stage 5D comprised 4 men and 5 women, ranging in age from 37 to 65 years (mean 56). None of the patients had kidney stones, bowel disease, hypercalcemia, hypermagnesemia, or hypophosphatemia (serum $P < 0.8$ mM). In Stage 3 CKD, 4 patients had Type II diabetes and 7 had hypertension, while 4 had Type II diabetes and 8 had hypertension with Stage 5D.

Patients stopped their calcium or magnesium supplements and phosphate binders for 1 week after enrollment and before starting the study, and omitted these medications throughout the study period. They underwent a 2-phase crossover trial lasting 1 week per phase, with 1 week or longer washout between phases. In one phase, they took EffCaMgCit one sachet three times daily with meals for a week. In the other phase, they received CaAc with the same dosing frequency and duration. In each group of subjects (Stage 3 or 5D), the sequence of treatment phases was randomized.

Each sachet of EffCaMgCit, containing 7.5 mmoles $\text{Ca}^{2+}$, 5 mmoles $\text{Mg}^{2+}$, 20 mEq $\text{H}^{+}$, and 15 mmoles citrate, was dissolved in water before ingestion. Each sachet of CaAc, containing 7.5 mmoles $\text{Ca}^{2+}$ and 15 mmoles acetate, was suspended in water before ingestion. EffCaMgCit and CaAc were purchased from Sterling Pharmaceutical Services (Dupo, IL) as research drugs. Sachets were identical appearance and identified by different lot numbers.

In patients with Stage 3 CKD, a venous blood sample was obtained at 2 h after ingesting a low calcium meal without EffCaMgCit or CaAc, on the day before each phase started (Day 0). On the 7th day of each phase, a venous blood sample was again taken at 2 h after taking a dose of either EffCaMgCit or CaAc with a similar meal. In patients with Stage 5D CKD, blood sample was obtained from the dialysis vascular access 2 h after ingesting a low calcium meal with or without a test medication.

Serum samples were analyzed for metabolic panel (including calcium, phosphorus, and creatinine) by Quest Diagnostics. UT Southwestern’s Mineral Metabolism Laboratory performed serum magnesium (atomic absorption

### Table 1 Therapeutic effects of EffCaMgCitrate on pathophysiologic intermediates

| Components of Eff-CaMgCit | Inhibition of CPP | Phosphate binding | PTH suppression | Magnesium supplement | Alkali supplement |
|---------------------------|------------------|------------------|----------------|----------------------|------------------|
| Ca                        | √                | √                | √              | √                    |                  |
| Mg                        | √                | √                | √              |                      |                  |
| Citrate                   | √                | √                | √              |                      | √                |

Springer
spectrophotometry), citrate (citrate lyase), intact parathyroid hormone (PTH) (immunoassay, Biomerica), and C-carboxyterminal telepeptide (CTX) (immunoassay, Immunodiagnostics Systems). Frozen serum samples were sent to Calciscon (Nidau-Biel, Switzerland) for T50 analysis [10]. To determine serum supersaturation index of octacalcium phosphate (SI OCP), activity product of OCP was calculated accounting for binding of calcium to albumin and globulin and for soluble complexes of calcium and phosphate, using the JESS computer program [23]. Octacalcium phosphate (Ca₄H(PO₄)₃) is a presumed precursor of calcification.

**Statistical analysis**

Mixed-effects linear models were used to compare responses between EffCaMgCit and CaAc treatments. These model included factors for treatment, study day, and interaction between treatment and day; the study participant was modeled as a random effect. Contrasts from these models were used to construct pair-wise comparisons and 95% confidence intervals. Treatment sequence was also assessed in the models and of treatment order had no effect. Skewed variables were analyzed after a logarithmic transformation. All statistical analyses were performed using SAS 9.3 (SAS Institute, Cary, NC). Two-sided P values of < 0.05 were considered statistically significant.

**Results**

**Serum magnesiu, citrate and T50**

In Stage 3 CKD, serum magnesium rose only slightly by 0.08 mM ($P = 0.07$) following EffCaMgCit treatment; it did not change after CaAc (top left, Fig. 1; Table 2). In Stage 5D CKD, however, EffCaMgCit produced a striking increase in serum Mg by 0.24 mM ($P < 0.0001$), whereas CaAc did not (top right, Fig. 1; Table 3). In Stage 3 CKD, EffCaMgCit produced a significant but slight increase in serum citrate whereas CaAc elicited no change (middle left, Fig. 1; Table 2). In Stage 5D CKD, serum citrate was lower than in Stage 3 and it did not change significantly after receiving either EffCaMgCit or CaAc (middle right, Fig. 1; Table 3).

In Stage 3 CKD, T50 was not significantly altered by either EffCaMgCit or CaAc (bottom left, Fig. 1; Table 2). In Stage 5D, however, T50 was markedly increased on EffCaMgCit (63%, $P = 0.013$), but not by CaAc (bottom right, Fig. 1; Table 3).

**Serum phosphate, calcium, and supersaturation index of octacalcium phosphate (SI OCP)**

In Stage 3 CKD, serum phosphate did not change during CaAc but increased numerically but did not reach statistical significance ($P = 0.06$) on EffCaMgCit (top left, Fig. 2; Table 2). In Stage 5D, serum phosphate marginally declined by 0.58 mM from baseline on EffCaMgCit and by 0.52 mM on CaAc (top right, Fig. 2; Table 3).

Both EffCaMgCit and CaAc increased serum Ca in Stage 3 as well as in Stage 5D CKD (middle, Fig. 2; Tables 2, 3). In Stage 3, serum SI OCP did not change on CaAc but rose significantly on EffCaMgCit (bottom left, Fig. 2; Table 1). In Stage 5D, serum SI OCP declined non-significantly on both EffCaMgCit and CaAc (bottom right, Fig. 2; Table 2).

**Serum PTH and bicarbonate**

In Stage 3 and Stage 5D, both EffCaMgCit and CaAc significantly reduced serum PTH, probably by raising serum Ca
(top, Fig. 3; Tables 1, 2). Serum bicarbonate (CO$_2$) did not change with either EffCaMgCit or CaAcS in Stage 3 (middle left, Fig. 3; Table 1). However, in Stage 5D, bicarbonate rose significantly on EffCaMgCit but not on CaAc (middle right, Fig. 3; Table 2).

Other parameters

In Stage 3 CKD, EffCaMgCit marginally reduced serum CTX, and CaAc significantly lowered it (Table 1). In Stage 5D CKD, baseline serum CTX was higher than in Stage 3. Both EffCaMgCit and CaAc significantly reduced serum CTX (Table 2).

In Stage 3 CKD, serum creatinine was modestly elevated at baseline and did not change following treatment with EffCaMgCit or CaAc (Table 1). In Stage 5D CKD, baseline serum creatinine was much higher than in Stage 3. Serum creatinine was unchanged by treatment with either EffCaMgCit or CaAc (Table 2).

Discussion

EffCaMgCit, a mixture derived from calcium carbonate, magnesium citrate and citric acid, was specially designed to meet the projected goal of this intervention. The amount of Ca$^2+$ delivered (7.5 mmoles thrice daily) was sufficient to suppress parathyroid function modestly but not too high to cause adynamic bone disease or increased risk of vascular calcification [24]. The Mg$^{2+}$ content was designed to be just...
below the threshold of oral Mg\textsuperscript{2+} in the induction of diarrhea [25]. There was citrate excess to H\textsuperscript+ directed toward confering a net base load and also to assure complete solubility of Ca\textsuperscript{2+} and Mg\textsuperscript{2+} salts. Calcium acetate was used as a comparator instead of placebo as it would have been unethical not to treat hyperphosphatemia in patients with stage 5D CKD. In stage 3 CKD, use of calcium acetate as a comparator ensured that the effect of the study drug is superior than the standard therapy rather than no therapy. The findings of this feasibility study fulfilled our expectations, with a few surprises.

As expected, EffCaMgCit profoundly increased serum Mg\textsuperscript{2+} in Stage 5D CKD, with a serum Mg\textsuperscript{2+} increment of 0.24 mM (\(P<0.0001\)), whereas CaAc did not. This prominent magnesium response attests to optimum solubility and bioavailability and renal retention of Mg\textsuperscript{2+}. In Stage 3 CKD, however, EffCaMgCit elicited only a marginal rise in serum Mg\textsuperscript{2+} of only 0.08 mM (\(P=0.07\)). We speculate that the absorbed Mg\textsuperscript{2+} from EffCaMgCit was largely eliminated in urine in subjects with Stage 3 CKD with adequate residual renal function and not in subjects with stage 5D CKD with little or no residual renal function (urinary parameters were not evaluated in these subjects).

In Stage 3 CKD, EffCaMgCit significantly increased serum citrate by 25 mM (\(P < 0.01\)). In Stage 5D CKD, serum citrate was lower than Stage 3, and increased nonsignificantly by 0.02 mM following EffCaMgCit treatment. In both Stage 3 and Stage 5D CKD, CaAc did not affect serum citrate.

Our initial hypothesis was that EffCaMgCit might retard CPP formation by increasing both serum Mg\textsuperscript{2+} and citrate thereby inhibiting formation of calcium phosphate (Table 1). In an in vitro system, Mg\textsuperscript{2+} delays the conversion of primary CPP (smaller nanoparticles initially formed) to secondary CPP (larger agglomerate) [10]. In the urinary space, citrate is a potent inhibitor of calcium oxalate agglomeration [20]. We believed citrate might have a similar action on calcium phosphate-fetuin agglomeration, and thus CPP formation. The results from the feasibility study suggest that the retained Mg\textsuperscript{2+} seen in the setting of reduced renal function, rather than a change in serum citrate, likely contributed to inhibition of CPP formation. Thus, from the standpoint of inhibition of CPP, CKD Stage 5D appeared to be the ideal target population of EffCaMgCit treatment.

EffCaMgCit might confer cardioprotection in CKD by means other than inhibition of CPP formation. As mentioned above, there are other benefits of
EffCaMgCit- namely phosphate binding, Mg\(^{2+}\) provision, alkali therapy, and suppression of PTH (Table 1).

EffCaMgCit provides an optimally soluble and bioavailable Mg\(^{2+}\) load. In patients undergoing hemodialysis, the well-known serum phosphate-associated increase in cardiovascular mortality was attenuated, in fact nearly abolished, among those in the highest tertile of serum Mg\(^{2+}\) concentration [22]. In a meta-analysis of trials on phosphorus binders, the addition of Ca\(^{2+}\) appeared to increase, whereas added Mg\(^{2+}\) appeared to reduce, the all-cause mortality [24]. In a meta-analysis of various trials, Mg\(^{2+}\) supplementation increased serum Mg\(^{2+}\) and lowered blood pressure [26]. In patients with CKD, hypomagnesemia was associated with increased mortality and decline in eGFR [27]. Increase in dialysate magnesium level in dialysate decreased serum Calcium precipitation propensity in patients with ESRD [28]. The exact pathogenic mechanism by which Mg\(^{2+}\) confers protection against cardiovascular complications in CKD is unknown. It might involve a scheme that is dependent on or independent of inhibition of CPP formation [29].

EffCaMgCit is potentially an efficient phosphate-binding agent, since it delivers already both solubilized calcium and magnesium capable of binding dietary phosphate instantly. In our study, EffCaMgCit reduced serum phosphate by 0.58 mM in Stage 5D; but this change was of marginal statistical significance probably due to low power. CaAc also reduced serum phosphate due to binding by calcium. EffCaMgCit should theoretically be more effective than CaAc due to additional phosphate-binding by Mg\(^{2+}\), but this study did not reveal a significant interaction between the two drugs probably due to inadequate power. Owing probably to the decline in serum phosphate (by intestinal binding) and increased complexation of circulating phosphate (by increased serum Mg\(^{2+}\)), EffCaMgCit reduced the circulating activity product of octacalcium phosphate, a driving force for CPP formation, by 35% but this decline was not statistically significant and was without significant interaction from CaAc. Thus, we conclude that the retardation of CPP formation by EffCaMgCit disclosed in Stage 5d is probably due mostly to the inhibitory effect of increased serum Mg\(^{2+}\). It might be partially due to reduced saturation of circulating calcium phosphate, but a larger number of patients would have to be evaluated.

Turning to another potentially beneficial effect of EffCaMgCit, a higher serum bicarbonate associated with a lower incidence of end stage renal disease and small randomized controlled trials have shown retardation of CKD progression [21, 30–35]. EffCaMgCit provide a robust alkali load, since it delivers non-metabolizable cations (calcium and magnesium) and metabolizable anion (citrate). EffCaMgCit increased serum bicarbonate in CKD Stage 5D. EffCaMgCit should be advantageous over the usual alkali therapy since it is devoid of potassium and sodium load which be harmful in CKD.

Lastly, EffCaMgCit used in CKD Stage 5D maintained serum PTH within the recommended desired range of 32 pM, without over-suppression to increase the risk of adynamic bone disease. The amount of calcium delivered by EffCaMgCit in this study (7.5 mmoles per dose three times per day) is lower than from the usual dose of calcium acetate used in CKD [36]. This precaution appeared to produce desired parathyroid suppression without incurring excessive risk of adynamic bone disease.

In conclusion, the strengths of our feasibility trial include demonstrating a potential promise of EffCaMgCit in averting cardiovascular complications of CKD Stage 5D by means of a substantial reduction in the propensity for CPP formation by increasing serum magnesium, with a tendency toward decreasing serum phosphate and saturation with respect to precursor phase of calcium phosphate. Moreover, it provided a potentially beneficial magnesium and alkali load. One of our limitations is the lack of urinary parameters to more objectively explain the lack of these effects in the stage 3 CKD subjects.

**Acknowledgements** The authors would like to thank Marsha Roberts for nursing support, John Pindexter for data management and analysis, Beverley Huet-Adams for statistical advice, Faye Britton for administrative assistance, and the technical staff of the Mineral Metabolism Laboratory. This work was supported by the Biotechnology Program of the Charles and Jane Pak Center for Mineral Metabolism and Clinical Research. Drs. Moe and Sakhaee are also supported by National Institutes of Health (P30 DK-079328, R01 DK081423, R01 DK091392).

**Compliance with ethical standards**

**Conflict of interest** The results presented in this paper have not been published previously in whole or part. Drs. Moe, Sakhaee and Pak are co-inventors on issued patent 9,539,283. Dr. Pasch is the co-inventor of the T50-test and co-founder of Calciscon, an entity which commercializes the T50-test. Dr. Pasch is also the current CEO of Calciscon and holds stock in the company. Drs. Quinones and Hamdi have no conflicts of interest to report.

**Ethical approval** All protocols were approved by the Institutional Review Boards at UT Southwestern and DaVita.

**Informed consent** Informed consent was obtained from all individual participants included in the study.

**Open Access** This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.
References

1. GBD (2016) Global, regional, and national incidence, prevalence, and years lived with disability for 328 diseases and injuries for 195 countries, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016 (2017). Lancet 390(10100):1211–1259. https://doi.org/10.1016/s0140-6736(17)32154-2

2. Grams ME, Chow EK, Segev DL, Coresh J (2013) Lifetime incidence of CKD stages 3–5 in the United States. Am J Kidney Dis 62(2):245–252. https://doi.org/10.1053/j.ajkd.2013.03.009

3. System USRD (2015) United States Renal Data System. 2017 USRDS annual data report: Epidemiology of kidney disease in the United States. National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, 2017

4. Glasscock RJ, Pecuts-Filho R, Barberato SH (2009) Left ventricular mass in chronic kidney disease and ESRD. Clin J Am Soc Nephrol 4(Suppl 1):S79–S91. https://doi.org/10.2215/cjn.04860709

5. Hruska KA, Choi ET, Memon I, Davis TK, Mathew S (2010) Cardiovascular risk in chronic kidney disease (CKD): the CKD-mineral bone disorder (CKD-MBD). Pediatr Nephrol 25(4):769–778. https://doi.org/10.1007/s00467-009-1337-0

6. Molemdia DG, Perazella MA (2016) PPs and kidney disease: from AIN to CKD. J Nephrol 29(5):611–616. https://doi.org/10.1007/s40620-016-0309-2

7. Russo D, Bellasi A, Pota A, Russo L, Di Iorio B (2015) Effects of phosphorus-restricted diet and phosphate-binding therapy on outcomes in patients with chronic kidney disease. J Nephrol 28(1):73–80. https://doi.org/10.1007/s40620-014-0071-2

8. Heiss A, Pipich V, Jahnen-Dechent W, Schwahn D (2010) Fetuin-A is a mineral carrier protein: small angle neutron scattering provides new insight on Fetuin-A controlled calcification inhibition. Biophys J 99(12):3986–3995. https://doi.org/10.1016/j.bpj.2010.03.030

9. Hamano T, Matsui I, Mikami S, Tomida K, Fujiwara N, Imai E, Takahashi Y, Isaka Y, Committee of Renal Data Registry of the Japanese Society for Dialysis T (2014) Magnesium modifies the cardiovascular mortality risk associated with hyperphosphatemia in patients undergoing hemodialysis: a cohort study. PLoS One 9(12):e116273. https://doi.org/10.1371/journal.pone.0116273

10. Panichi V, Bigazzi R, Paoletti S, Mantuano E, Beati S, Marchetti V, Berranini G, Grazi G, Giust R, Rosati A, Miglieri M, Pasquarriello A, Panicucci E, Barsotti G, Bellasi A (2010) Impact of calcium, phosphate, PTH abnormalities and management on mortality in hemodialysis: results from the RISCARD study. J Nephrol 23(5):556–562

11. Cunningham J, Locatelli F, Rodriguez M (2011) Secondary hyperparathyroidism: pathogenesis, disease progression, and therapeutic options. Clin J Am Soc Nephrol 6(4):913–921. https://doi.org/10.2215/cjn.06404010

12. Dobre M, Rahman M, Hostetter TH (2015) Current status of bicarbonate in CKD. J Am Soc Nephrol 26(3):515–523. https://doi.org/10.1681/asn.2014202205

13. Felsenfeld AJ, Levine BS, Rodriguez M (2015) Pathophysiology of calcium, phosphorus, and magnesium dysregulation in chronic kidney disease. Seminars in dialysis 28(6):564–577. https://doi.org/10.1111/sdi.12411

14. Kok DJ, Papapoulos SE, Bijvoet OL (1986) Excessive crystal agglomeration with low citrate excretion in recurrent stone-formers. Lancet 1(8489):1056–1058

15. Banerjee T, Crews DC, Wesson DE, Tileo AM, Saran R, Rios-Burrows N, Williams DE, Pwee NR, Centers for Disease C, Prevention Chronic Kidney Disease Surveillance T (2015) High dietary acid load predicts ESRD among adults with CKD. J Am Soc Nephrol 26(7):1693–1700. https://doi.org/10.1681/ASN.2014040332

16. Panichi V, Bigazzi R, Paoletti S, Mantuano E, Beati S, Marchetti V, Berranini G, Grazi G, Giust R, Rosati A, Miglieri M, Pasquarriello A, Panicucci E, Barsotti G, Bellasi A (2010) Impact of calcium, phosphate, PTH abnormalities and management on mortality in hemodialysis: results from the RISCARD study. J Nephrol 23(5):556–562

17. Cunningham J, Locatelli F, Rodriguez M (2011) Secondary hyperparathyroidism: pathogenesis, disease progression, and therapeutic options. Clin J Am Soc Nephrol 6(4):913–921. https://doi.org/10.2215/cjn.06404010

18. Dobre M, Rahman M, Hostetter TH (2015) Current status of bicarbonate in CKD. J Am Soc Nephrol 26(3):515–523. https://doi.org/10.1681/asn.2014202205

19. Felsenfeld AJ, Levine BS, Rodriguez M (2015) Pathophysiology of calcium, phosphorus, and magnesium dysregulation in chronic kidney disease. Seminars in dialysis 28(6):564–577. https://doi.org/10.1111/sdi.12411

20. Kok DJ, Papapoulos SE, Bijvoet OL (1986) Excessive crystal agglomeration with low citrate excretion in recurrent stone-formers. Lancet 1(8489):1056–1058

21. Banerjee T, Crews DC, Wesson DE, Tileo AM, Saran R, Rios-Burrows N, Williams DE, Pwee NR, Centers for Disease C, Prevention Chronic Kidney Disease Surveillance T (2015) High dietary acid load predicts ESRD among adults with CKD. J Am Soc Nephrol 26(7):1693–1700. https://doi.org/10.1681/ASN.2014040332

22. Sakaguchi Y, Fujii N, Shoji T, Hayashi T, Nakagawa H, Iseki K, Tsukihara Y, Isaka Y, Committee of Renal Data Registry of the Japanese Society for Dialysis T (2014) Magnesium modifies the cardiovascular mortality risk associated with hyperphosphatemia in patients undergoing hemodialysis: a cohort study. PLoS One 9(12):e116273. https://doi.org/10.1371/journal.pone.0116273

23. Pak CY, Moe OW, Maalouf NM, Zerwekh JE, Poinexter J, Adams-Huet B (2009) Comparison of semi-empirical and computer derived methods for estimating urinary saturation of brushite. J Urol 181(3):1423–1428. https://doi.org/10.1016/j.juro.2008.10.141

24. Sekercioglu N, Thabane L, Diaz Martinez JP, Nesrallah G, Longo CJ, Busse JW, Akhtar-Danesh N, Agarwal A, Al-Khalifah R, Iorio A, Guyatt GH (2016) Comparative effectiveness of Phosphate binders in patients with chronic kidney disease: a systematic review and network meta-analysis. PLoS one 11(6):e0156891. https://doi.org/10.1371/journal.pone.0156891

25. Fine KD, Santa Ana CA, Fordtran JS (1991) Diagnosis of magnesium-induced diarrhoea. N Engl J Med 324(15):1012–1017. https://doi.org/10.1056/nejm199104113241502

26. Zhang X, Li Y, Del Gobbo LC, Rosanoff A, Wang J, Zhang W, Song Y (2016) Effects of magnesium supplementation on blood pressure: a meta-analysis of randomized double-blind placebo-controlled trials. Hypertension 68(2):324–333. https://doi.org/10.1161/hypertensionaha.116.07664

27. Van Laecke S, Nagler EV, Verbeke F, Van Biesen W, Vanholder R (2013) Hypomagnesaemia and the risk of death and GFR decline in chronic kidney disease. Am J Med 126(9):825–831. https://doi.org/10.1016/j.amjmed.2013.02.036

28. Bressendorff I, Hansen D, Schou M, Pasch A, Brandi L (2018) The effect of increasing dialysate magnesium on serum calcification propensity in subjects with end stage kidney disease: a randomized, controlled clinical trial. Clin J Am Soc Nephrol 13(9):1373–1380. https://doi.org/10.2215/cjn.13921217

29. Floege J (2015) Magnesium in CKD: more than a calcification inhibitor? J Nephrol 28(3):269–277. https://doi.org/10.1007/s40620-014-0140-6

30. Abramowicz MK, Melamed ML, Bauer C, Raff AC, Hostetter TH (2013) Effects of oral sodium bicarbonate in patients with CKD.
31. de Brito-Ashurst I, Varagunam M, Raftery MJ, Yaqoob MM (2009) Bicarbonate supplementation slows progression of CKD and improves nutritional status. J Am Soc Nephrol 20(9):2075–2084. https://doi.org/10.1681/asn.2008111205

32. Goraya N, Simoni J, Jo CH, Wesson DE (2014) Treatment of metabolic acidosis in patients with stage 3 chronic kidney disease with fruits and vegetables or oral bicarbonate reduces urine angiotensinogen and preserves glomerular filtration rate. Kidney Int 86(5):1031–1038. https://doi.org/10.1038/ki.2014.83

33. Mahajan A, Simoni J, Sheather SJ, Broglio KR, Rajab MH, Wesson DE (2010) Daily oral sodium bicarbonate preserves glomerular filtration rate by slowing its decline in early hypertensive nephropathy. Kidney Int 78(3):303–309. https://doi.org/10.1038/ki.2010.129

34. Mircescu G, Garneata L, Stancu SH, Capusa C (2007) Effects of a supplemented hypoproteic diet in chronic kidney disease. J Renal Nutr 17(3):179–188. https://doi.org/10.1053/j.jrn.2006.12.012

35. Phisitkul S, Hacker C, Simoni J, Tran RM, Wesson DE (2008) Dietary protein causes a decline in the glomerular filtration rate of the remnant kidney mediated by metabolic acidosis and endothelin receptors. Kidney Int 73(2):192–199. https://doi.org/10.1038/sj.ki.5002647

36. Block GA, Spiegel DM, Ehrlich J, Mehta R, Lindbergh J, Dreisbach A, Raggi P (2005) Effects of sevelamer and calcium on coronary artery calcification in patients new to hemodialysis. Kidney Int 68(4):1815–1824. https://doi.org/10.1111/j.1523-1755.2005.00600.x